These data further support the regulatory effect of Ikaros on both BCL6 and BACH2 in B-ALL patients; they also reveal that IKZF1 deletion may be responsible for high BCL6 and low BACH2 expression in patients. The gene discussed is BACH2; the disease is acute lymphoblastic leukemia.